|
|
|
|
|
市場調査レポート
遺伝子療法の発展状況と市場潜在力
Gene Therapy: Worldwide Current Development Status and Market Potential
|
当商品の販売は、2011年07月19日を持ちまして終了しました。
While research and development of gene therapy has experienced its share of hurdles in recent years, it has also begun demonstrating its potential.
As a result of the technical sophistication and aggressive development by commercial and academic entities, the continued financial support evincing
its real promise, and the unabated clinical need of numerous patient populations, gene therapy is indeed headed toward market approval and
introduction by the end of this decade.
This report will be a detailed assessment of the status of development in gene therapy and the outlook for its commercial introduction. The
report will detail the techniques, technologies, and target clinical applications being pursued, with detailed data and insights on specific products
and the numerous competitors vying to reach the market. The report will provide a well-grounded assessment of the remaining clinical and
commercial hurdles, providing a ten-year outlook for genetically based therapies. The report's analysis will reveal windows of opportunity for current
or hopeful competitors.
Executive Summary
Section 1: Introduction to Gene Therapy
- History
- Technologies
- Clinical targets
- Challenges
- The ethical and regulatory dimension
Section 2: Technology
- Gene insertion
- Genes to correct deficiencies
- Genes to enhance immune function
- Gene targeting
- Gene silencing
- Antisense compounds
- RNA interference
Section 3: Gene Delivery: Viral Vectors
- Adenoviruses
- Adeno-associated viruses
- Retroviruses
- Herpes simplex virus
- Lentiviruses
- RNA viruses
- Main companies developing viral vectors
- AlphaVax Inc
- ALZA Corporation
- AMDL Inc
- Amsterdam Molecular Therapeutics
- Applied Genetic Technologies Corporation
- Ariad Gene Therapeutics
- Ark Therapeutic
- Austrianova Biotherapeutics
- AVAX Technologies
- Aventis Gencell
- Avigen Inc
- Bavarian Nordic A/S
- BD Biosciences Clontech
- Biogen-IDEC
- Canji Inc
- Cell Genesys Inc
- Ceregene Inc
- Collateral Therapeutics Inc
- Crucell NV
- DNAVEC Research Inc
- Enzo Biochem Inc
- GenEra S.p.A.
- Genetic Therapy Inc
- Genetix Pharmaceuticals Inc
- GenVec Inc
- Genzyme Corp.
- Got-a-Gene AB
- Henogen
- Imgenex In.
- Introgen Therapeutics Inc
- InvivoGen
- MediGene AG
- Merck & Co Inc
- MFIC Corporation
- ML Laboratories
- Molecular Medicine Bioservices Inc
- Nature Technology Corporation
- Onyx Pharmaceuticals
- Oxford Biomedica plc
- Phogen Ltd
- Qbiogene
- Takara Biomedical Group
- Targeted Genetics Corporation
- Therion Biologics Corporation
- Transgene S.A.
- VIRxSYS Corporation
Section 4: Gene Delivery: Non-Viral Vectors
- Cells
- Liposomes
- DNA
- Other vectors
- Main companies developing non-viral vectors
- Cells
- Ariad Gene Therapeutics
- Cardion AG
- CellGenix Technologie Transfer GmbH
- Enzo Biochem Inc
- GenEra S.p.A.
- ML Laboratories
- NeuralSTEM Inc
- Neurotech SA
- NsGene A/S
- Schering AG
- Sirna Therapeutics (formerly Ribozyme Pharmaceutical Inc
- Targeted Genetics Corporation
- Liposomes
- AntiCancer Inc
- G.O.T. GmbH & Co. KG
- Genteric Inc
- Genzyme Corp.
- IC-Vec Ltd
- Imperial College Innovations Ltd
- Invitrogen Inc
- ML Laboratories
- Polyplus-transfection SAS
- Qbiogene
- Qiagen
- Regulon Inc
- Targeted Genetics Corporation
- Transgene
- Valentis Inc
- Vical Incorporated
- DNA
- Aldevron LLC
- Althea Technologies Inc
- Copernicus Therapeutics Inc
- CytRx Corporation
- Genencor International Inc
- Mirus Corporation
- Mologen Holding AG
- Nucleonics Inc
- Qiagen
- Supratek Pharma Inc
- Tosk Inc
- Transkaryotic Therapies (TKT) Inc
- Vical Incorporated
- Wyeth Lederle Vaccines
- Other Vectors
- Athersys Inc
- Chromos Molecular Systems Inc
- Expression Genetics Inc
- Insert Therapeutics Inc
- Intradigm Corporation
- REPLICor Inc
- Sangamo BioSciences Inc
- Symbiontics Inc
- Vion Pharmaceuticals Inc
Section 5: Clinical Targets: Single-Gene Deficiencies
- Cystic fibrosis
- Other diseases
section 6: Clinical Targets: Cancers
- Breast cancer
- Prostate cancer
- Melanoma
- Lung cancer
- Head & Neck cancer
- Other cancers
Section 7: Clinical Targets: Infections
- HIV/AIDS
- Other infections
Section 8: Other Clinical targets
- Cardiovascular conditions
- CNS conditions
- Tissue repair
- Other
Section 9: Market Opportunities
- Prevalence of major target diseases
- Market potential for gene therapies
- Leading companies in product development
- Companies serving the gene therapy industry
Section 10: Challenges
- Technical hurdles
- Adverse events
- The ethical debate
- Regulatory and patent issues
Section 11: Company Profiles (Partial List)
- US Companies
- Aastrom
- AlphaVax
- Alza
- Ariad
- Aventis Gencell
- Avigen
- Bio-Rad
- Cell Genesys, Inc.
- Collateral Therapeutics
- Copernicus Therapeutics
- Corautus Genetics
- CytoGenix
- Enzo Biochem
- Gene Therapy Systems
- Genetronics Biomedical Corp.
- GenVec, Inc.
- Genzyme Corp.
- Introgen Therapeutics
- InVivogen
- Merck & Co
- Mirus
- Onyx Pharmaceuticals
- RheoGene
- Schering Plough
- Selective Genetics
- Sirna Therapeutics
- Targeted Genetics
- Valentis
- Vical
- European companies
- AustriaNova Biotherapeutics
- Bavarian Nordic
- NSGene
- Transgene
- MolMed
- Modex Therapeutics
- ML Laboratories
- Oxford Biomedica
- Phogen
- Canadian companies
- AngioGene
- Chromos Molecular Systems
- Australian companies
- Antisense Therapeutics
- Benitec
- Asian company
Section 12: The Future
- Expert Views
- Technologies Most Likely to Succeed
- Clinical Targets Most Likely to Benefit
- Companies Most Likely to Prosper
Appendix I: Science Background to Gene Therapy
Appendix II: Glossary
Appendix III: Company Addresses
|
 |
